AG
CTMX icon

Artal Group’s CytomX Therapeutics CTMX Stock Holding History

Artal Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-178,600
Closed -$1.19M – 137
2020
Q3 		$1.19M Sell
178,600
-9,400
-5% -$69.7K 0.03% 128
2020
Q2 		$1.57M Buy
+188,000
New +$1.75M 0.04% 128
2019
Q2 		– Sell
-200,000
Closed -$2.15M – 108
2019
Q1 		$2.15M Buy
200,000
+50,000
+33% +$739K 0.09% 95
2018
Q4 		$2.27M Buy
+150,000
New +$2.23M 0.08% 91

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's CTMX Position: Q4 2020 in Review

Artal Group sold out of CytomX Therapeutics (CTMX) in Q4 2020, closing a stake of 178,600 shares — an estimated $1.19M sold.

Artal Group first reported a position in CTMX in Q4 2018 and held it in 4 quarters. The position peaked at $2.27M in Q4 2018. 126 funds tracked by Wall St. Rank hold CTMX as of Q4 2020.

  • Artal Group reported no remaining CytomX Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Artal Group sold 178,600 CytomX Therapeutics shares in Q4 2020, an estimated $1.19M.
  • Artal Group first reported a position in CytomX Therapeutics in Q4 2018 and held it in 4 quarters.
  • Artal Group's CytomX Therapeutics position peaked at $2.27M in Q4 2018.
  • 126 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.